| Toxicity |
Interacting Protein |
Mechanism |
Reference |
| Alzheimers Disease | Apolipoprotein E (P02649) | Alzheimer?s disease [ ADR Type 2 ] | Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
|
| Anorexia | Cholinesterase precursor (P06276) | The asthenia and anorexia adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
|
| Asthenia | Cholinesterase precursor (P06276) | The asthenia and anorexia adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
|
| Diarrhoea | Cholinesterase precursor (P06276) | The diarrhoea adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
|
| Dizziness | Cholinesterase precursor (P06276) | The dizziness adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
|
| Hepatotoxicity | Cytochrome P450 1A2 (P05177) | CBT will not be clinically useful in determining the subset of patients most susceptible to tacrine hepatotoxicity However@ the correlation between CBT results and tacrine blood levels is the first evidence supporting a critical role for CYP1A2 activity in the disposition of the drug in vivo [ ADR Type 2 ] | The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity
|
| Nausea | Cholinesterase precursor (P06276) | The nausea and vomiting adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
|
| Vomiting | Cholinesterase precursor (P06276) | The nausea and vomiting adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
|